
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is advancing towards a Phase 3 registration trial for its personalized cancer vaccine candidate, IFx-2.0, which targets resistance to established cancer immunotherapies, particularly by complementing Keytruda in treating advanced Merkel Cell Carcinoma. The company's strategic focus on addressing primary resistance in immuno-oncology positions it favorably within a growing market, suggesting significant potential for revenue generation as clinical results progress positively. Furthermore, the innovative approach of IFx-2.0 enhances its prospects for successful commercialization, reflecting strong momentum in the company’s operational and financial trajectory.
Bears say
TuHURA Biosciences reported a net loss of $0.15 per share in 1Q25, which was consistent with previous estimates of a $0.12 loss, indicating ongoing financial challenges. The company faces several significant risks that could adversely affect its financial performance and stock outlook, including potential negative clinical results for its personalized cancer vaccine candidate, IFx-2.0, and delays in advancing pipeline candidates toward regulatory approval. Additionally, competitive pressures from other checkpoint inhibitors and the risk of long-term dilution further compound the negative sentiment surrounding TuHURA's stock prospects.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares